Find Clinical Trials

Inclusion Criteria: 1. Patients whose blood pressure measurements taken at community hospitals meet the hypertension criteria outlined in the Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 revision); 2. Aged 60-75 years old; 3. Have certain abilities in reading, comprehension, and communication; 4. Able to use a smartphone; 5. In the pre-conscious/conscious/preparatory stage. 6. Volunteer to participate in this study and sign the informed consent form. Exclusion Criteria: 1. Exclude those with a history of severe heart, brain, kidney diseases or cancer; 2. Patients who currently have or have previously had mental disorders; 3. Patients who are currently participating in other research projects.

Inclusion Criteria: * Age: Patients between the ages of 4 and 17 years (asthma) and 3-17 years (ENT) * Diagnosis: o Asthma patients: Diagnosed with mild-to-moderate and severe persistent asthma according to Global Initiative for Asthma (GINA) guidelines, with a history of symptoms or exacerbations requiring medical intervention (prior prednisone course and/or albuterol for \>24 hours in context of acute wheezing episode) in the past 12 months. ENT patients: Diagnosed with common ENT conditions such as acute otitis media (AOM) or strep pharyngitis in the prior year. Diagnosis must be based on established clinical guidelines. * Technology access: Must have access to a smartphone, tablet, or other device capable of running the Medentum Diagnostik platform app and access to Wifi or cellular service. * Care access: Must be receiving routine care from University of Arizona or associated clinics in Arizona and have active health insurance * Consent: Must have parental or guardian consent for participation, as well as child assent when appropriate.(all children ≥7 yrs) Exclusion Criteria: * Other medical conditions: Patients with additional chronic lung diseases (such as cystic fibrosis) requiring complex specialist care will be excluded. cerebral palsy, neurodevelopmental conditions, congenital heart disease. Patients with complex chronic conditions or chronic ENT conditions requiring complex specialist care will be excluded. * Recent surgical/complex ENT medical history: Patients who have had tympanostomy tubes or tonsillectomy/adenoidectomy, patients with chronic ENT conditions including chronic suppurative or serous otitis media * Recent medical history: Patients who have experienced severe asthma exacerbations requiring hospitalization or intensive treatment in the past 4 weeks * Comorbidities: Patients with speech delays, hearing impairments, or cognitive impairments that may affect their ability to use the Diagnostik platform accurately will be excluded. * Non-compliance risk: Patients or families that are unable to follow study instructions, comply with follow-up visits, or properly use the Medentum platform will be excluded.

Inclusion Criteria: * ASA physical status II or III. * Age ≥ 18 years. * Singleton pregnancy, cephalic presentation * No contraindications to neuraxial anesthesia and voluntarily requesting labor analgesia for planned vaginal delivery Exclusion Criteria: * History of bipolar disorder, psychiatric disorders, or suicidal ideation * Severe cardiac, cerebral, hepatic, or renal disease * Allergy to α2-adrenergic receptor agonists * Baseline bradycardia (heart rate \< 60 bpm) or cardiac conduction abnormalities before labor analgesia * Hypotension (systolic blood pressure \< 90 mmHg) before labor analgesia * History of drug or alcohol abuse * Severe rhinitis or nasal cavity deformity

Inclusion Criteria: * The inclusion criteria for this study will be BCS who are between 18 and 50 years of age with early-stage breast cancer (stage I-III) treated with curative intent. * They should be within two years of initial diagnosis. * Patients scoring 0-1 on the Eastern Cooperative Oncology Group (ECOG) scale will be accepted. * Patients should have completed chemo, surgery, and/or radiation components of their planned therapy regimen at least 6 months ago; they should be positive for estrogen-receptor breast cancer and currently on anti-estrogen therapy (tamoxifen, aromatase inhibitors: letrozole, anastrozole, exemestane). * Eligible patients will be screened for distress using the IES-R scale. Individuals with scores greater than or equal to 24, will be included in the study. * Individuals must also be motivated to attend a 3-day virtual workshop, which requires a total commitment of approximately 12 hours virtually. * They must be willing to participate in a weekly zoom group session for 8-weeks after attending the workshop and then once monthly afterwards up until the 6-month follow up data collection. * They must be willing to do a 10-20-minute daily practice at home, at least 3 times a week, during the 6-month follow-up period. * They should also be prepared for three clinical visits (one hour each) for specimen and blood collection at baseline, week 8, and 6 months, as well as three additional visits (15 minutes each) for wearable data upload. * A subset of participants (n=10) selected for MRI will be screened for claustrophobia and those qualifying (CLQ \<25) will be selected for MRI sub-study (exploratory aim of this study). * If selected for MRI sub-study, two additional clinical visits (one hour each) will be required. Exclusion Criteria: * Male patients are excluded. * Individuals with a recent history (within past three months) of cardiac arrhythmia, unstable or uncontrolled respiratory disorders such as COPD or asthma, or myocardial infarction, angina. * Individuals with a recent history (within past three months) of schizophrenia or bipolar disorder, those currently engaging in active substance abuse involving illicit drugs (excluding marijuana), those experiencing active violent ideation, or those on lithium-based medication regimens will also be excluded. Current or recent (within three months) suicidal impulse or suicide attempt is exclusionary, although suicidal ideation without intent or impulse is not. * Participants with an Eastern Cooperative Oncology Group (ECOG) score of 2 or higher * Breast cancer patients receiving CDK 4/6 inhibitor-based regimens or GnRH antagonist regimens, will not be eligible. * Patients with IES-R scores less than or equal to 23 will be excluded from the study. * Recent surgery (within 3 months) is not excluded unless, in the opinion of the research team, it would substantially interfere with the ability of the person to participate in the intervention. * Prisoners, pregnant women, and non-English-speaking individuals will not be included. * A subset of participants (n=10) selected for MRI will be screened for claustrophobia and those with a tendency towards claustrophobic events (CLQ \>25) will be excluded from MRI scanning.

Inclusion Criteria: * 18-65 years of age * BMI between 25- 49.9 kg/m2 * Live in a southern state (as classified by the US Census) * Be able to complete all survey assessments via computer or phone * Have a wi-fi connection at home or other site to access Zoom-delivered interventions * Have three or more type 2 diabetes risk factors (NIDDK Risk factors for T2DM) * Own a digital body weight scale, have regular access, or be willing to purchase one Exclusion Criteria: * Currently participating in a weight loss program or taking weight loss medications * Has lost more than 10 pounds in the past 6 months * Diagnosed with major health or psychiatric diseases, drug or alcohol dependency, thyroid conditions, diabetes, or pregnancy * Pregnant (or have been pregnant in the last 6 months), anticipating on becoming pregnant in the next 3 months, or currently breastfeeding * Diagnosed with an eating disorder as screened by the Eating disorder Screen for Primary care \[ESP\].

Inclusion Criteria: * Female/ Male of 18 years old or more * With Type 2 Diabetes * Treated with GLP 1 analog for more than 3 months * Signed consent * ASA between I and IV Exclusion Criteria: * Insuline treatment * Gastro intestinal motility disorders * Past gastric surgery * Hiatal hernia * Recent trauma * Inability to be lay down for the exam * Inability to follow the instructions for the exam (language, dementia) * BMI \> 40 * Inability to stop smoking 12h before the measures

Inclusion Criteria: * Female gender, age over 18 years. * Diagnosis of infertility with indication for In Vitro Fertilization (IVF). * Patients on the waiting list at HC-UFMG. * Agreement not to practice other mind-body or herbal complementary therapies during the study. * DASS-21 screening score compatible with at least mild anxiety, stress, and/or depression. * No aversion to inhaling essential oil or synthetic lavender essence. Exclusion Criteria: * Severe neurological, psychiatric, or clinical disorders (e.g., schizophrenia, severe depression) that prevent participation. * Use of medications that could confound the primary outcome (e.g., sleep medications, anxiolytics, antidepressants, neuroleptics) in the 30 days prior to or during the study. * Known allergy to lavender products. * Pregnancy during the study period. * Use of essential oils in the last 90 days.

In CHS 1: Inclusion criteria: \- Individuals insured by the CHS since birth and with at least 10 years of follow up. Exclusion criteria: \- Termination of insurance and lack of successive medical follow up. In CHS 2: Inclusion criteria: * Active diagnosis of schizophrenia in CHS registries during stages of analyses * Place of residence is at the CHS hospital catchment areas (to ensure psychiatric hospitalisation is fully registered). Exclusion criteria: \- Lack of active diagnosis and place of residency outside of CHS catchment area.

Inclusion Criteria: * Being over 18 years of age * Knowing their diagnosis * Receiving chemotherapy for the first time due to a breast cancer diagnosis * Having breast cancer stages I, II, or III (stage 4 patients were not included in the study as metastatic spread would increase symptoms and make communication with the patient difficult), * Not receiving treatment for another cancer, * Not having a physical disability that would prevent telephone interviews (hearing, speech), * Not having any psychiatric disorder that would impair comprehension and understanding, * Patients who have verbally and in writing consented to participate in the study will be included in the research. Exclusion Criteria: * Patients with communication problems • Patients with psychiatric problems

Inclusion Criteria: * Aged 18-50 years of age * Capacity to give informed consent to participate in the study * Able to comply with study requirements and visits * Meet the criteria for mild-severe stress levels (scores between 15-33) as assessed by DASS-42 Stress Subscale * Normal or corrected to normal vision and/or hearing Exclusion Criteria: * Current smoker * Having food allergies and/or intolerances * Current diagnosis of Type 1 or 2 diabetes, cardiometabolic disease, or psychiatric or neurological conditions (e.g. schizophrenia, dementia) including eating disorders * Current or previous diagnosis of depression in past 6 months * Currently receiving medications that lower cholesterol, blood pressure, blood glucose levels, or improve insulin sensitivity * Receiving antidepressant or anti-anxiety medications or treatments * Receiving hormonal birth control * Perimenopause or menopause * Pregnancy, lactation, or an intent to become pregnant during the course of the study * Continuous antibiotic use for \> 3 days within 1 month prior to enrolment * Continuous use of weight-loss drug for \> 1 month before screening * Major change in dietary intake in past month (e.g. excluding whole food groups) * Consuming a restricted diet, including a vegan, vegetarian, and ketogenic diet * Currently consuming daily prebiotic or probiotic supplements * Any significant GI condition affecting absorption including (but not limited to) inflammatory bowel disease, weight loss surgery, irritable bowel syndrome. * Active cancer, or treatment for any cancer, in last 3 years * Consuming more than 20g of fibre a day as assessed by the FiberScreen

Inclusion Criteria: * Age is 18-75 years old, gender is female * Postoperative pathological examination confirmed HR+, HER2- invasive breast cancer: 1. ER positivity and/or PR positivity is defined as: all positively stained tumor cells The proportion of tumor cells is ≥10%; 2. HER2 negativity is defined as: 0/1+ by standard immunohistochemistry (IHC) test; ISH test was negative. * The time from radical surgery or breast-conserving surgery to randomization shall not exceed 6 months; * Postoperative pathological examination after radical surgery revealed the presence of lymph nodes in the axilla on the ipsilateral side of the breast lesion. Metastasis (lymph node micrometastases, ipsilateral internal mammary lymph nodes and supraclavicular lymph nodes are allowed) metastasis, but the number of metastases to the ipsilateral internal mammary lymph nodes and supraclavicular lymph nodes is not included in the positive calculation of sexual lymph nodes), the specific requirements are as follows: 1\) The number of lymph node metastases is ≥ 4; 2) When the number of lymph node metastases is 1 to 3, at least one of the following high-risk factors must be met: i. Postoperative pathological examination shows that the diameter of the primary tumor is ≥5cm; ii. The histological grade of the primary tumor is grade III (excluding grade II-III); iii. There is residual invasive cancer in breast lesions after neoadjuvant treatment; iv. Ki-67≥30%. * Eastern Cooperative Oncology Group (ECOG) physical status score is 0 -2 points. * With my consent and having signed the informed consent form, I am willing and able to comply with the planned interview. inspections, study treatment plans, laboratory tests, and other research procedures. Exclusion Criteria: * Pathological examination diagnosed as HER2-positive breast cancer (HER2-positive definition: standard immune Histochemistry (IHC) test is 3+ or ISH test is positive). * Local or regional recurrence of breast malignant tumors. * The clinical stage of the tumor is stage IV (metastatic) breast cancer. * Bilateral breast cancer (including contralateral carcinoma in situ). * History of serious lung diseases such as interstitial pneumonia. * Have received CDK4/6 inhibitor treatment or other anti-tumor biological treatments in the past therapy, targeted therapy or tumor immunotherapy. * Have undergone major surgical operations, any investigational drugs, or others within 4 weeks before randomization Anticancer treatment or use of immunomodulators (excluding surgery, chemotherapy, radiotherapy and endocrine therapy). * The presence of other serious physical or mental illnesses or laboratory abnormalities that may increase participation The risks of the research, or interference with the research results, and the researcher's opinion that he is not suitable to participate in this research study patients.

Inclusion Criteria: * Age ≥18 years * Confirmed diagnosis breast cancer for which surgical procedure is needed * Planned for breast conserving surgery Exclusion Criteria: * Person that undergoes breast amputation without confirmed cancer diagnosis

Inclusion Criteria: * Postmenopausal women diagnosed with invasive breast cancer by core needle biopsy or vacuum-assisted biopsy * Unifocal * Lesion ≤ 2 cm (on ultrasound and contrast enhanced mammography) * No axillary lymphadenopathy on ultrasound * No axillary lymph node involvement on ultrasound. * Luminal tumor (estrogen and/or progesterone receptor positive) * HER2 negative * Signed informed consent Exclusion Criteria: * Infiltrating lobular carcinoma * Extensive in situ component * Multifocality or multicentricity * Contraindication for contrast mammography * Not candidate for surgery * Distant metastasis -

Inclusion Criteria: * Male and female patients aged 18 to 65 years * Diagnosis of Major Depressive Disorder according to DSM-5 at the time of study participation * Provision of voluntary informed consent Exclusion Criteria: * Intellectual disability * Severe neurological disorders * Comorbid psychiatric diagnoses * Depressive disorder secondary to an organic medical condition * Depressive disorder secondary to substance use

Inclusion Criteria: * Female gender * Age 18-45 years (childbearing period) * Body Mass Index (BMI) ≥40 kg/m² or ≥35 kg/m² with obesity-related comorbidities, meeting international criteria for bariatric surgery * Scheduled for primary bariatric surgery (sleeve gastrectomy or Roux-en-Y gastric bypass) * Presence of a stable, sexually active intimate partner relationship * Sexually active * Willingness to participate and provide informed consent * Ability to complete Arabic-language questionnaires Exclusion Criteria: * Women who are not sexually active * Post-menopausal women (amenorrhea ≥12 months without other cause) * Current pregnancy or lactation * History of medication use that can interfere with sexual function, including: * Antidepressants * Antipsychotics/psychotropic drugs * Beta-blockers * Spironolactone * Hormonal contraceptives (unless stable for ≥3 months and continued throughout study) * Hormone replacement therapy * Major uncontrolled medical conditions: * Chronic heavy smoker (smoking index ≥400 pack-years) * History of pelvic floor surgery or gynecological malignancy * Partner with known erectile dysfunction or use of erectile dysfunction medications * Previous bariatric surgery (revisional procedures) * Inability or unwillingness to provide informed consent

Inclusion Criteria: * At least 65 years old * Body mass index: 25-40 kg/m\^2 * Female: Waist to hip ratio \>0.8 * Male: Waist to hip ratio \>1.0 * Free from structured exercise during the prior 6 months (mo) weight stable for the prior 6 months T2D group: -Diagnosed by a physician with elevated glycosylated hemoglobin (HbA1c) \>6.5% Control group: -Normoglycemic with HbA1c levels not exceeding 5.6% and fasting blood glucose levels below or equal to 99 mg/dL (5.5mmol) Exclusion Criteria: * Uncontrolled diabetes (evidence of HbA1c \> 10%, prescription of insulin) * Diagnoses of diabetic neuropathy or failing diabetic neuropathy screening * Statins * Peripheral edema Consumption of ergogenic-levels of dietary supplements that may affect muscle mass (e.g., creatine, HMB), insulin-like substances, or anabolic/catabolic pro-hormones (e.g., DHEA) within 6 weeks prior to participation. * Untreated hypothyroidism, epilepsy, medications that affect vasoactivity, possibility of pregnancy, and any neurological, cardiovascular, or musculoskeletal disease that precludes exercise testing.

Inclusion Criteria: * Between the ages of 18 and 65 * Fluent in English (and therefore able to provide consent) * Currently living in New York State * Access to at least one device with internet and video-conferencing capabilities * High self-reported worry, rumination, and/or self-criticism * Meet Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5) criteria for at least one, current psychological disorder Exclusion Criteria: * Active suicidal ideation or intent * Substance dependence disorder, schizophrenia, bipolar-I disorder, or a primary DSM-5 diagnosis of borderline or narcissistic personality disorder * Currently in therapy or receiving any type of psychosocial treatment * Individuals taking psychotropic mediation that has not been stabilized for a period of at least 3 months * Current students at Teachers College, Columbia University

Inclusion Criteria: * Age 3-17 years * Intensive care unit admission * Treatment for critical asthma Exclusion Criteria: * History of unrepaired critical congenital heart disease * History of cystic fibrosis * Active tracheostomy dependence

Inclusion Criteria: 1. A clinical, radiological, or histologic diagnosis of cirrhosis of any etiology. 2. Splenomegaly with secondary hypersplenism. 3. No evidence of portal vein thrombosis by ultrasound evaluation and angio-CT prior to surgery. 4. Underwent laparoscopic splenectomy at our center. 5. Orally received 2.5 mg of apixaban (CTTQ, Nanjing, China) twice daily or a 100 mg aspirin tablet (Bayer, Leverkusen, Germany) once daily for 6 months from POD 3. 6. subcutaneous injections of low molecular weight heparin sodium (CSBio, Hebei, China) were administered for 5 days from POD 3 7. Oral dipyridamole (Henan Furen, Henan, China) at a dosage of 25 mg, administered three times daily for 3 months from POD 3. 8. Had no imaging evidence (Doppler ultrasound or CT) of portal vein thrombosis during postoperative months 6 to 12. 9. Developed portal vein thrombosis after 12 months post-surgery. 10. Provided informed consent to participate in the study. Exclusion Criteria: 1. Hepatocellular carcinoma or any other malignancy. 2. Hypercoagulable state other than the liver disease related. 3. DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs. 4. Portal hypertension bleeding . 5. Child - Pugh C 6. Recent peptic ulcer disease 7. History of Hemorrhagic stroke 8. Pregnancy. 9. Uncontrolled Hypertension 10. Human immunodeficiency virus (HIV) infection

Inclusion Criteria: 1. Live birth, term (≥37 weeks) delivery at Massachusetts General Hospital 2. Access to Patient Gateway, as to receive the electronic EPDS scale 3. Primary obstetric provider at MGH or its affiliated clinics 4. No recent history of depressive disorder as determined through diagnoses or medication use\* 5. Age ≥18 years old Exclusion Criteria: 1. A diagnosis code in the EHR for major depressive disorder, bipolar disorder, or psychotic disorder within the year prior to delivery 2. Antidepressant, antipsychotic, or bipolar medication use within the year prior to delivery 3. Age \<18 years old